BeiGene Biotech Secures RMB 520 Million Series B Funding to Accelerate Development and Clinical Translation of Off-the-Shelf Immune Cell Therapies

On March 25, Nanjing Bioheng Biotech Co., Ltd. (hereinafter referred to as “Bioheng Biotech”), an innovative biopharmaceutical company focused on the development and commercialization of universal immune cell therapy products, announced the completion of its RMB 520 million Series B financing round. The round was co-led by GL Ventures, Decheng Capital, and Octagon Capital, with participation from BlueRun Ventures China and Shenzhen Capital Group Co., Ltd. (SCGC). BFC served as the financial advisor for this financing round.

Dr. He Xiaohong, Founder and Chairman of Bioheng Biotech, stated, “We are deeply honored to have secured the recognition of top-tier investment institutions in the biopharmaceutical sector and the continued support of our existing shareholders in this funding round. Bioheng Biotech is dedicated to the development of universal cell immunotherapy technologies and has achieved notable progress in preclinical research for hematologic and other related cancers. With the proceeds from this financing round, the company will further strengthen its talent pipeline, increase investment in R&D projects and clinical drug development, and further refine its product pipeline and commercialization strategy. We also extend our sincere gratitude to all Bioheng employees for their unwavering dedication and perseverance. We hope to soon bring new hope to the clinical treatment of cancer patients by providing an affordable cell therapy drug accessible globally.”

Dr. Cui Xiangmin, Managing Partner at Decheng Capital, stated, “It is an honor to continue supporting the company in Bioheng’s Series B financing round. We are bullish on the company’s technological innovation and leadership in the field of cell therapy, and we have strong confidence in its development trajectory since inception. Over the past two years, the company’s R&D pipeline has progressively expanded, with clinical advancements proceeding rapidly and in an orderly manner, demonstrating its strong execution capabilities.”

Jia Ting, Founder and Chief Investment Officer of Bafang Capital, stated, “The team at Bioheng Biotech possesses a clear scientific vision, a strong spirit of collaboration, and an unwavering commitment to innovation. We are delighted to have the opportunity to partner with such a team and look forward to providing long-term companionship and support for the company’s development.”

Responsible Editor: Liuli

Disclaimer: This article is reproduced from Yaozhi.com. The copyright belongs to the original author. The purpose of this reproduction is to convey more information, and it does not represent the views of this platform. If there are any issues regarding the content, copyright, or other matters, please leave a message on our website, and we will remove the content promptly.